According to Regeneron Pharmaceuticals's latest financial reports the company's current EPS (TTM) is $37.36. In 2022 the company made an earnings per share (EPS) of $40.52 a decrease over its 2021 EPS that were of $76.45.
Year | EPS | Change |
---|---|---|
2023 (TTM) | $37.36 | -7.8% |
2022 | $40.52 | -47% |
2021 | $76.45 | 133.36% |
2020 | $32.76 | 69.13% |
2019 | $19.37 | -14.44% |
2018 | $22.64 | 100.71% |
2017 | $11.28 | 31.78% |
2016 | $8.56 | 38.96% |
2015 | $6.16 | 72.55% |
2014 | $3.57 | -17.55% |
2013 | $4.33 | -44.98% |
2012 | $7.87 | -422.54% |
2011 | -$2.44 | 92.13% |
2010 | -$1.27 | 49.41% |
2009 | -$0.85 | -15.84% |
2008 | -$1.01 | -36.88% |
2007 | -$1.60 | -9.6% |
2006 | -$1.77 | 4.12% |
2005 | -$1.70 | -323.68% |
2004 | $0.76 | -135.51% |
2003 | -$2.14 | -24.38% |
2002 | -$2.83 | 56.35% |
2001 | -$1.81 |
Company | EPS | EPS differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | $14.09 | -62.30% | ๐บ๐ธ USA |
Novartis NVS | $3.74 | -89.99% | ๐จ๐ญ Switzerland |
Amgen AMGN | $14.15 | -62.13% | ๐บ๐ธ USA |
Sanofi SNY | $3.18 | -91.49% | ๐ซ๐ท France |
Biogen BIIB | $18.46 | -50.59% | ๐บ๐ธ USA |
Alnylam Pharmaceuticals
ALNY | -$4.11 | -111.00% | ๐บ๐ธ USA |